StockNews.AI
REVB
StockNews.AI
9 hrs

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

1. Revelation Biosciences reports positive Phase 1b results for CKD treatment. 2. Gemini normalizes inflammatory response, indicating breakthrough potential in inflammation diseases.

Earnings
-17.38%Current Return
VS
+0.24%S&P 500
$2.8209/09 08:10 AM EDTEvent Start
$2.3309/09 04:31 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

Positive clinical trial results can lead to increased investor confidence and stock price rise, similar to successes seen in biotech sectors, such as with CRISPR Therapeutics following positive trial outcomes.

How important is it?

The article highlights significant clinical advancements which can drive stock interest and market activity, indicating a high likelihood of influencing REVB's price.

Why Short Term?

The announcement's immediate effect on stock price is expected, particularly ahead of the upcoming data discussion webcast.

Related Companies

CRSPPCVXSGMO
- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be held on Wednesday, September 10th at 8:30 am Eastern Time SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced positive safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met.

Related News